Tyagarajan Seshu sold $84K of CADL
Tyagarajan Seshu (Chief Technology Officer) sold 7,000 shares of Candel Therapeutics, Inc. (CADL) at $12.00 on 2026-08-17 under a Rule 10b5-1 trading plan.
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CADL
Neutral
high confidence
Mentioned
$CADL
Relevance
2/10
Decision brief
The 30-second read
01
Why it matters
The disclosed sale is modest and pre‑arranged, offering little new trading insight.
02
Market read
Limited relevance; typical insider sale with minimal market effect.
03
Timing
post‑market 2026-08-17 filing
Relevance 2/10Novelty 4/10Timing: post‑market 2026-08-17 filing
Background
SEC Form 4 filing reports insider transaction for Candel Therapeutics (CADL).
Company-level read
Ticker impact
Context
Form 4 disclosed CTO sold 7,000 shares for $84K via 10b5-1 plan on 2026-08-17.
Expected impact
No significant impact expected.
Evidence & confidence
Sale size is small relative to total holdings and market cap; typical for pre‑arranged plans.
Market effects
Sector
none
Regional
none
Global
none
Key entities
- companyCandel Therapeutics, Inc.
Biotech firm listed on NASDAQ under CADL.
- personTyagarajan Seshu
Chief Technology Officer of CADL.